News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
219,615 Results
Type
Article (7391)
Company Profile (37)
Press Release (212185)
Multimedia
Podcasts (33)
Webinars (7)
Section
Business (55646)
Career Advice (175)
Deals (10673)
Drug Delivery (52)
Drug Development (12452)
Employer Resources (35)
FDA (5834)
Job Trends (5368)
News (87149)
Policy (8695)
Tag
Academia (706)
Accelerated approval (12)
Adcomms (4)
Allergies (58)
Alliances (15324)
ALS (24)
Alzheimer's disease (420)
Antibody-drug conjugate (ADC) (75)
Approvals (6113)
Artificial intelligence (255)
Autoimmune disease (36)
Automation (12)
Bankruptcy (66)
Best Places to Work (4869)
BIOSECURE Act (4)
Biosimilars (119)
Biotechnology (16)
Bladder cancer (59)
Brain cancer (11)
Breast cancer (204)
Cancer (1229)
Cardiovascular disease (160)
Career advice (171)
Career pathing (2)
CAR-T (49)
CDC (10)
Cell therapy (147)
Cervical cancer (13)
Clinical research (11464)
Collaboration (577)
Compensation (65)
Complete response letters (9)
COVID-19 (783)
CRISPR (24)
C-suite (340)
Cystic fibrosis (27)
Data (1764)
Decentralized trials (1)
Denatured (12)
Depression (45)
Diabetes (170)
Diagnostics (3404)
Digital health (28)
Diversity (4)
Diversity, equity & inclusion (11)
Drug discovery (68)
Drug pricing (85)
Drug shortages (7)
Duchenne muscular dystrophy (75)
Earnings (19174)
Editorial (22)
Employer branding (1)
Employer resources (32)
Events (50660)
Executive appointments (416)
FDA (7093)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (3)
Frontotemporal dementia (9)
Funding (539)
Gene editing (47)
Generative AI (22)
Gene therapy (141)
GLP-1 (275)
Government (1415)
Grass and pollen (4)
Guidances (169)
Healthcare (8685)
HIV (31)
Huntington's disease (4)
IgA nephropathy (30)
Immunology and inflammation (44)
Immuno-oncology (8)
Indications (38)
Infectious disease (877)
Inflammatory bowel disease (53)
Inflation Reduction Act (7)
Influenza (31)
Intellectual property (58)
Interviews (15)
IPO (4333)
IRA (20)
Job creations (715)
Job search strategy (155)
JPM (57)
Kidney cancer (1)
Labor market (16)
Layoffs (88)
Leadership (3)
Legal (1668)
Liver cancer (20)
Longevity (4)
Lung cancer (141)
Lymphoma (108)
Machine learning (12)
Management (14)
Manufacturing (210)
MASH (69)
Medical device (6319)
Medtech (6346)
Mergers & acquisitions (6833)
Metabolic disorders (450)
Multiple sclerosis (79)
NASH (5)
Neurodegenerative disease (72)
Neuropsychiatric disorders (25)
Neuroscience (745)
Neurotech (1)
NextGen: Class of 2026 (2906)
Non-profit (1552)
Now hiring (4)
Obesity (198)
Opinion (86)
Ovarian cancer (43)
Pain (47)
Pancreatic cancer (29)
Parkinson's disease (46)
Partnered (12)
Patents (92)
Patient recruitment (108)
Peanut (19)
People (19205)
Pharmaceutical (12)
Pharmacy benefit managers (15)
Phase 1 (2430)
Phase 2 (4050)
Phase 3 (5439)
Pipeline (1908)
Policy (91)
Postmarket research (735)
Preclinical (788)
Press Release (10)
Prostate cancer (81)
Psychedelics (8)
Radiopharmaceuticals (82)
Rare diseases (254)
Real estate (1422)
Recruiting (12)
Regulatory (7169)
Reports (18)
Research institute (640)
Resumes & cover letters (13)
Rett syndrome (18)
RNA editing (3)
RSV (27)
Schizophrenia (48)
Series A (96)
Series B (83)
Service/supplier (3)
Sickle cell disease (32)
Special edition (7)
Spinal muscular atrophy (42)
Sponsored (12)
Startups (1244)
Stomach cancer (2)
Supply chain (36)
Tariffs (24)
The Weekly (21)
Vaccines (241)
Venture capital (45)
Weight loss (119)
Women's health (51)
Worklife (2)
Date
Today (7)
Last 7 days (207)
Last 30 days (688)
Last 365 days (10615)
2026 (1344)
2025 (10972)
2024 (11921)
2023 (13066)
2022 (20211)
2021 (21556)
2020 (20910)
2019 (17773)
2018 (13129)
2017 (8988)
2016 (9589)
2015 (11009)
2014 (8133)
2013 (6711)
2012 (7000)
2011 (6967)
2010 (5591)
Location
Africa (238)
Alabama (19)
Alaska (1)
Arizona (101)
Arkansas (6)
Asia (11529)
Australia (1525)
California (3408)
Canada (1077)
China (333)
Colorado (224)
Connecticut (150)
Delaware (117)
Europe (28140)
Florida (526)
Georgia (134)
Hawaii (2)
Idaho (22)
Illinois (393)
India (48)
Indiana (217)
Iowa (2)
Japan (198)
Kansas (26)
Kentucky (23)
Louisiana (18)
Maine (28)
Maryland (428)
Massachusetts (2530)
Michigan (144)
Minnesota (242)
Mississippi (2)
Missouri (86)
Montana (5)
Nebraska (13)
Nevada (40)
New Hampshire (30)
New Jersey (1303)
New Mexico (7)
New York (1101)
North Carolina (599)
North Dakota (1)
Northern California (1721)
Ohio (133)
Oklahoma (7)
Oregon (13)
Pennsylvania (913)
Puerto Rico (4)
Rhode Island (15)
South America (315)
South Carolina (24)
Southern California (1289)
Tennessee (106)
Texas (508)
United States (13791)
Utah (169)
Virginia (82)
Washington D.C. (29)
Washington State (247)
West Virginia (3)
Wisconsin (43)
Wyoming (1)
219,615 Results for "viiv healthcare".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
ViiV Healthcare showcases breadth of clinical and real-world evidence at EACS and IDWeek 2025
October 10, 2025
·
20 min read
Press Releases
ViiV Healthcare announces 96-week data reaffirming Dovato is as effective as Biktarvy in maintaining virological suppression of HIV-1 with significantly less weight gain
October 20, 2025
·
13 min read
Infectious disease
Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and ViiV will push forward with their long-acting antivirals after touting positive early-stage results.
March 12, 2025
·
2 min read
·
Tristan Manalac
Press Releases
ViiV Healthcare presents new data demonstrating positive real-world impact of its innovative long-acting injectables for HIV at IAS 2025
July 9, 2025
·
15 min read
Infectious disease
GSK, ViiV Tout 99% Effectiveness for Long-Acting HIV PrEP as Gilead Gains Ground
Real-world evidence show that GSK and ViiV Healthcare’s long-acting pre-exposure prophylaxis Apretude can prevent nearly all HIV infections, while rival Gilead Sciences is moving quickly toward an approval for a twice-yearly option.
October 17, 2024
·
2 min read
·
Tristan Manalac
Business
Exavir Therapeutics Announces Entry Into a Litigation Settlement and License Agreement For Ultra-Long-Acting HIV Compounds With ViiV Healthcare
Today, Exavir Therapeutics announced that the company has entered into a settlement and license agreement with ViiV Healthcare for ultra-long-acting HIV compounds.
May 22, 2024
·
1 min read
Infectious disease
Gilead, GSK/ViiV, Merck Present New HIV PrEP Frontiers at IAS25
HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the heels of the landmark Yeztugo approval.
July 15, 2025
·
4 min read
·
Tristan Manalac
FDA
ViiV Healthcare announces U.S. FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV
ViiV Healthcare announces U.S. FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV.
April 8, 2024
·
10 min read
Press Releases
ViiV Healthcare data show 89% of treatment-naïve people with HIV choose to switch to long-acting injectable Vocabria + Rekambys from daily pills after achieving rapid viral suppression
July 15, 2025
·
14 min read
WHO Warns of Growing Resistance in Individuals to GSK, ViiV’s HIV Drug Tivicay
The World Health Organization has detected signals of growing HIV resistance to GSK and ViiV Healthcare’s Tivicay, which it says must be minimized as part of the broader global response to antimicrobial resistance.
March 6, 2024
·
2 min read
·
Tristan Manalac
1 of 21,962
Next
